Maples and Calder Advises Biohaven Pharmaceutical on US$195m IPO Maples and Calder Advises Biohaven Pharmaceutical on US$195m IPO
01 Jun 2017
Maples and Calder has advised Biohaven Pharmaceutical Holding Company Ltd ("Biohaven") on its initial public offering ("IPO") on the New York Stock Exchange, which closed in May 2017 at approximately US$195 million.
The Maples and Calder team was led by BVI-based partners Richard May and Chris Newton with the assistance of associate Daniel Perkins. "Transactions such as these highlight the flexibility of the BVI as a jurisdiction and the suitability of BVI entities for a wide range of uses, including IPOs," said Maples and Calder's BVI Managing Partner, Richard May. "We are pleased to have assisted Biohaven on this significant achievement and look forward to continuing to work with them as the business progresses." A long standing client of the firm, Maples and Calder has acted as Biohaven's legal adviser since its incorporation and continues to advise the company on its corporate matters.
The infrastructure includes proprietary applications as well as industry-leading technologies to support the delivery of innovative solutions to alternative investment and UCITS funds.Read more
06 Aug 2020
The restructuring was supported by the successful appointment of the first ever provisional liquidators in the BVI.Read more
29 Jul 2020
Maples and Calder, the Maples Group's law firm, is pleased to share that The Legal 500 EMEA 2020 has recognised its lawyers and practices across its Dublin, Luxembourg and Dubai offices.Read more
27 Jul 2020
The Maples Group has announced enhancements to its fund services offering for private debt and credit funds via integrated IHS Markit loan market data feeds.Read more
21 Jul 2020